Table 3.
Results of the univariate and multivariate analyses of certain factors for overall survival rates after palliative RT in125 patients with available scores of STAS
| |
|
Univariate |
Multivariate |
||
|---|---|---|---|---|---|
| |
|
MST |
|
OR |
|
| n | (mos) | p | (95% CI) | p | |
| Gender |
|
||||
| M |
76 |
4.5 |
0.20 |
- |
- |
| F |
49 |
6.3 |
|
|
|
| Age | |||||
| < 70 |
47 |
5.6 |
0.65 |
- |
- |
| ≧ 70 |
78 |
4.1 |
|
|
|
| Performance status | |||||
| 3 |
98 |
6.3 |
0.026 |
1.9 |
0.064 |
| 4 |
27 |
2.0 |
|
(1.0-3.9) |
|
| Concomitant disease* | |||||
| Yes |
14 |
26.8 |
0.011 |
4.5 |
0.0084 |
| No |
111 |
3.8 |
|
(1.5-13.7) |
|
| No. of tumor lesion | |||||
| 1-3 |
25 |
6.3 |
0.041 |
1.4 |
0.42 |
| ≧ 4 |
100 |
3.6 |
|
(0.6-3.1) |
|
| Irradiated site | |||||
| Bone |
71 |
4.7 |
0.94 |
- |
- |
| Others |
54 |
4.4 |
|
|
|
| Target of palliative RT | |||||
| Metastatic tumor |
97 |
3.8 |
0.14 |
- |
- |
| Primary tumor |
28 |
6.3 |
|
|
|
| Primary tumor site | |||||
| Lung |
51 |
3.4 |
0.020 |
2.2 |
0.011 |
| Others |
74 |
6.1 |
|
(1.2-3.9) |
|
| Total RT dose (Gy) | |||||
| <30 |
20 |
0.7 |
0.080 |
1.1 |
0.91 |
| ≧ 30 |
105 |
4.9 |
|
(0.4-2.7) |
|
| Completion of planned RT dose | |||||
| Yes |
109 |
5.0 |
0.0025 |
2.0 |
0.170 |
| No |
16 |
0.5 |
|
(0.7-5.2) |
|
| Chemotherapy | |||||
| Yes |
25 |
5.6 |
0.82 |
- |
- |
| No |
100 |
3.9 |
|
|
|
| Improvement of STAS score | |||||
| Yes |
76 |
6.4 |
0.0005 |
3.7 |
<0.0001 |
| No | 49 | 2.4 | (2.0-6.6) | ||
RT radiotherapy, STAS Support Team Assesment Schedule, MST median survival time, OR odds ratio, CI confidence interval.
*associated with a worse performance status.